GPCR

Boehringer Ingelheim and Sosei Heptares join forces to develop first-in-class treatments targeting all symptoms of schizophrenia

Retrieved on: 
Monday, March 11, 2024

While ‘positive’ symptoms can be stabilized with antipsychotics, some of which can have side effects, there are currently no approved medicines for ‘negative’ or cognitive symptoms.

Key Points: 
  • While ‘positive’ symptoms can be stabilized with antipsychotics, some of which can have side effects, there are currently no approved medicines for ‘negative’ or cognitive symptoms.
  • The development of a new schizophrenia treatment targeting GPR52 has the potential to address all three aspects of schizophrenia1,2 providing a novel precision treatment.
  • “We’re very excited to enter this partnership with Sosei Heptares with this novel approach, which aims to address a huge unmet need of those living with schizophrenia.
  • We’re delighted to partner with Boehringer Ingelheim and leverage its leading expertise in neurological disease research and innovation.

Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference

Retrieved on: 
Friday, March 8, 2024

SAN FRANCISCO, March 08, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced that Raymond Stevens, Ph.D., the Company’s Founder and Chief Executive Officer, will participate in a fireside chat at the Leerink Partners Global Biopharma Conference on Wednesday, March 13, 2024, at 8:00 AM ET in Miami, Florida.

Key Points: 
  • SAN FRANCISCO, March 08, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced that Raymond Stevens, Ph.D., the Company’s Founder and Chief Executive Officer, will participate in a fireside chat at the Leerink Partners Global Biopharma Conference on Wednesday, March 13, 2024, at 8:00 AM ET in Miami, Florida.
  • The live and archived webcast of the presentation will be accessible from the company’s website https://ir.structuretx.com/events-presentations/events .
  • The replay of the webcast will be available for 90 days.

Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights

Retrieved on: 
Friday, March 8, 2024

SAN FRANCISCO, March 08, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023, and highlighted recent corporate achievements.

Key Points: 
  • “In 2023 we demonstrated clear proof-of-concept with our lead GLP-1 receptor agonist, GSBR-1290, for obesity and type 2 diabetes.
  • This study is fully enrolled and data are expected in the latter half of the second quarter of 2024.
  • The Company plans to initiate a global Phase 2b obesity study of GSBR-1290 in the fourth quarter of 2024.
  • Net Loss: Net loss for the fourth quarter of 2023 totaled $24.5, with non-cash stock-based compensation expense of $2.1 million, compared to $11.9 million for the fourth quarter of 2022 with non-cash stock-based compensation expense of $0.6 million.

Orion Biotechnology Presenting at the 3rd GPCR-Targeted Drug Discovery Summit in Boston

Retrieved on: 
Thursday, March 7, 2024

Ottawa, Canada, March 06, 2024 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd. (Orion), a drug discovery and development company unlocking the therapeutic potential of previously undruggable G Protein-Coupled Receptors (GPCRs), today announced that it will be presenting at the 3rd GPCR-Targeted Drug Discovery Summit in Boston on March 7th.

Key Points: 
  • Ottawa, Canada, March 06, 2024 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd. (Orion), a drug discovery and development company unlocking the therapeutic potential of previously undruggable G Protein-Coupled Receptors (GPCRs), today announced that it will be presenting at the 3rd GPCR-Targeted Drug Discovery Summit in Boston on March 7th.
  • Dr. Oliver Hartley, Orion’s Vice President of Drug Discovery, will be presenting Orion’s PROcisionXTM discovery platform and its ability to unlock peptide and protein GPCRs with industry leading efficiency.
  • Additionally, Dr. Hartley will provide an update on Orion’s portfolio of GPCR-targeted therapeutics, including the recent discovery of both antagonists and agonists against GIPR and CXCR6.
  • Commenting on his presentation, Dr. Hartley said “I’m pleased to be presenting Orion’s technology and its ability to rapidly generate innovative therapies for metabolic and immunological diseases.

Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments

Retrieved on: 
Tuesday, March 5, 2024

Thus, an increase in the geriatric population is one factor driving the pancreatic cancer treatment market growth.

Key Points: 
  • Thus, an increase in the geriatric population is one factor driving the pancreatic cancer treatment market growth.
  • The incidence is significantly higher in the geriatric population above 65 years of age compared to other types of cancers.
  • A report from Fortune Business Insights said that: “the pancreatic cancer treatment market size is projected to grow to USD 6.85 billion by 2029, exhibiting a CAGR of 15.7% during 2022-2029.
  • Companies engaged in manufacturing cancer drugs have increased their focus on R&D activities to develop new drugs for pancreatic cancer treatment.

Certa Therapeutics’ FT011 Granted US FDA Fast Track for the Treatment of Systemic Sclerosis

Retrieved on: 
Monday, February 19, 2024

MELBOURNE, Australia, Feb. 19, 2024 (GLOBE NEWSWIRE) -- Certa Therapeutics (Certa), a biotechnology company developing innovative precision therapies for patients with inflammatory and fibrotic diseases, today announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its investigational therapy FT011 for the treatment of systemic sclerosis (scleroderma), having previously granted Orphan Drug Designation.

Key Points: 
  • MELBOURNE, Australia, Feb. 19, 2024 (GLOBE NEWSWIRE) -- Certa Therapeutics (Certa), a biotechnology company developing innovative precision therapies for patients with inflammatory and fibrotic diseases, today announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its investigational therapy FT011 for the treatment of systemic sclerosis (scleroderma), having previously granted Orphan Drug Designation.
  • [4]
    Professor Darren Kelly, Certa Therapeutics CEO and founder said, “We are thrilled to have received Fast Track Designation which supports further acceleration of the FT011 clinical development program.
  • Certa is progressing preparations toward a pivotal clinical trial of FT011 as a treatment for scleroderma.
  • C Denton, W Stevens, N Kruger, M Papadimitriou, F Khong, M Bradney, D Kelly, R Lafyatis “FT011 for the Treatment of Systemic Sclerosis.

Schrödinger Reports Strong Fourth Quarter and Full-Year 2023 Financial Results

Retrieved on: 
Wednesday, February 28, 2024

Cash used for operating activities in 2024 is expected to be above cash used for operating activities in 2023.

Key Points: 
  • Cash used for operating activities in 2024 is expected to be above cash used for operating activities in 2023.
  • For the first quarter of 2024, software revenue is expected to range from $33 million to $35 million.
  • “We had a very strong year in 2023, with significant growth in our software and drug discovery revenue and substantial progress in our proprietary pipeline and at our co-founded companies.
  • Schrödinger will host a conference call to discuss its fourth quarter and full year 2023 financial results on Wednesday, February 28, 2024, at 4:30 p.m.

Tectonic Therapeutic Announces Participation at Investor Conferences in March

Retrieved on: 
Tuesday, February 27, 2024

Tectonic Therapeutic, Inc. (“Tectonic”), a privately-held biotechnology company developing GPCR (G-protein coupled receptor)-targeted therapeutic proteins, co-founded by Timothy A. Springer and Andrew C. Kruse of Harvard Medical School, today announced that Alise Reicin, MD, President and Chief Executive Officer, will be participating in two investor conferences in March:

Key Points: 
  • Tectonic Therapeutic, Inc. (“Tectonic”), a privately-held biotechnology company developing GPCR (G-protein coupled receptor)-targeted therapeutic proteins, co-founded by Timothy A. Springer and Andrew C. Kruse of Harvard Medical School, today announced that Alise Reicin, MD, President and Chief Executive Officer, will be participating in two investor conferences in March:
    The Tectonic management team will host one-on-one meetings during both conferences.
  • Interested investors should contact their TD Cowen and/or Leerink representative to schedule meetings.

Domain Therapeutics Promotes Stephan Schann as Chief Scientific Officer (CSO)

Retrieved on: 
Tuesday, February 27, 2024

Domain Therapeutics (“Domain” or “the Company”), a clinical-stage global biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptors (GPCRs), today announces the expansion of the Company’s executive management team with the appointment of Stephan Schann as Chief Scientific Officer (CSO).

Key Points: 
  • Domain Therapeutics (“Domain” or “the Company”), a clinical-stage global biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptors (GPCRs), today announces the expansion of the Company’s executive management team with the appointment of Stephan Schann as Chief Scientific Officer (CSO).
  • Stephan will oversee the development of Domain’s proprietary pipeline and its highly innovative R&D center based in Strasbourg, France.
  • Stephan has also contributed significantly to the Company’s scientific achievements and strategic direction.
  • Dr. Tony Johnson, President and Chief Executive Officer of Domain Therapeutics, said: “We are thrilled to have Stephan be promoted into the role of Chief Scientific Officer.

AbbVie and OSE Immunotherapeutics Announce Partnership to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation

Retrieved on: 
Wednesday, February 28, 2024

NORTH CHICAGO, Ill. and NANTES, France, Feb. 28, 2024 /PRNewswire/ -- AbbVie Inc. (NYSE: ABBV) and OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage immunotherapy company, today announced a strategic partnership to develop OSE-230, a monoclonal antibody designed to resolve chronic and severe inflammation, currently in the pre-clinical development stage.

Key Points: 
  • OSE-230 is a first-in-class monoclonal antibody designed to activate ChemR23, a G-Protein Coupled Receptor (GPCR) target.
  • Activation of ChemR23 may offer a novel mechanism for the resolution of chronic inflammation, modulating functions of both macrophages and neutrophils.
  • "By leveraging our expertise in immunology drug development, we look forward to advancing OSE-230, which offers a novel mechanism-of-action to treat chronic inflammation."
  • Under the terms of the agreement, AbbVie will receive an exclusive global license to develop, manufacture and commercialize OSE-230.